These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23887296)

  • 1. Prognostic significance of tumor budding in rectal cancer biopsies before neoadjuvant therapy.
    Rogers AC; Gibbons D; Hanly AM; Hyland JM; O'Connell PR; Winter DC; Sheahan K
    Mod Pathol; 2014 Jan; 27(1):156-62. PubMed ID: 23887296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
    Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
    Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment response and tissue necrosis as prognostic indicators following neoadjuvant chemoradiotherapy in rectal cancer patients.
    Jung JH; An HJ; Kim HJ; Lee J; Lee KM; Kim SH; Cho HM; Shim BY
    Korean J Intern Med; 2016 Jan; 31(1):134-44. PubMed ID: 26767867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic value of tumor budding in patients who had surgery for rectal cancer with and without neoadjuvant therapy.
    Şirin AH; Sökmen S; Ünlü SM; Ellidokuz H; Sarioğlu S
    Tech Coloproctol; 2019 Apr; 23(4):333-342. PubMed ID: 30900039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer.
    Park IJ; You YN; Agarwal A; Skibber JM; Rodriguez-Bigas MA; Eng C; Feig BW; Das P; Krishnan S; Crane CH; Hu CY; Chang GJ
    J Clin Oncol; 2012 May; 30(15):1770-6. PubMed ID: 22493423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
    Jäger T; Neureiter D; Fallaha M; Schredl P; Kiesslich T; Urbas R; Klieser E; Holzinger J; Sedlmayer F; Emmanuel K; Dinnewitzer A
    Strahlenther Onkol; 2018 Nov; 194(11):991-1006. PubMed ID: 30069738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
    Alderdice M; Dunne PD; Cole AJ; O'Reilly PG; McArt DG; Bingham V; Fuchs MA; McQuaid S; Loughrey MB; Murray GI; Samuel LM; Lawler M; Wilson RH; Salto-Tellez M; Coyle VM
    Mod Pathol; 2017 Sep; 30(9):1287-1298. PubMed ID: 28621318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extramural perineural invasion in pT3 and pT4 rectal adenocarcinoma as prognostic factor after preoperative chemoradiotherapy.
    Lino-Silva LS; Salcedo-Hernández RA; España-Ferrufino A; Ruiz-García EB; Ruiz-Campos M; León-Takahashi AM; Meneses-García A
    Hum Pathol; 2017 Jul; 65():107-112. PubMed ID: 28526604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant-intensified treatment for rectal cancer: time to change?
    Musio D; De Felice F; Bulzonetti N; Guarnaccia R; Caiazzo R; Bangrazi C; Raffetto N; Tombolini V
    World J Gastroenterol; 2013 May; 19(20):3052-61. PubMed ID: 23716984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological grading based on poorly differentiated clusters is predictive of tumour response and clinical outcome in rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Reggiani Bonetti L; Lionti S; Domati F; Pagliani G; Mattioli E; Barresi V
    Histopathology; 2017 Sep; 71(3):393-405. PubMed ID: 28425130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
    Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
    J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Extranodal Extension in Rectal Cancer Patients Undergoing Radical Resection After Preoperative Chemoradiotherapy.
    Kim YI; Cho H; Kim CW; Park Y; Kim J; Ro JS; Lee JL; Yoon YS; Park IJ; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2021 Mar; 20(1):e35-e42. PubMed ID: 33191166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of metastatic lymph node regression grade after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
    Tominaga T; Akiyoshi T; Yamamoto N; Oba K; Nagasaki T; Yamaguchi T; Konishi T; Fukunaga Y; Ueno M
    Surgery; 2019 Dec; 166(6):1061-1067. PubMed ID: 31345564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy.
    Trotsyuk I; Sparschuh H; Müller AJ; Neumann K; Kruschewski M; Horst D; Elezkurtaj S
    BMC Cancer; 2019 Nov; 19(1):1033. PubMed ID: 31675950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomography with histological correlation for evaluating tumor regression of rectal carcinoma after preoperative chemoradiation therapy.
    Lee CT; Chow NH; Liu YS; Lin SC; Lin PC; Wu YH; Lee JC; Tsai HM
    Hepatogastroenterology; 2012; 59(120):2484-9. PubMed ID: 22497951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the pathological regression level of metastatic lymph nodes associated with oncologic outcomes following preoperative chemoradiotherapy in rectal cancer?
    Choi JP; Kim SJ; Park IJ; Hong SM; Lee JL; Yoon YS; Kim CW; Lim SB; Lee JB; Yu CS; Kim JC
    Oncotarget; 2017 Feb; 8(6):10375-10384. PubMed ID: 28060748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
    BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial.
    Battersby NJ; Dattani M; Rao S; Cunningham D; Tait D; Adams R; Moran BJ; Khakoo S; Tekkis P; Rasheed S; Mirnezami A; Quirke P; West NP; Nagtegaal I; Chong I; Sadanandam A; Valeri N; Thomas K; Frost M; Brown G
    Trials; 2017 Aug; 18(1):394. PubMed ID: 28851403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Preoperative Albumin-Globulin Ratio in Patients with Rectal Cancer Treated with Preoperative Chemoradiotherapy.
    Toiyama Y; Oki S; Okugawa Y; Ide S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Ohi M; Inoue Y; Araki T; Kusunoki M
    Oncology; 2018; 95(5):270-280. PubMed ID: 29996133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of C-Reactive Protein-to-Albumin Ratio with Rectal Cancer Patient Undergoing Chemoradiotherapy Followed by Surgery.
    Ide S; Toiyama Y; Okugawa Y; Oki S; Yasuda H; Fujikawa H; Yoshiyama S; Hiro J; Kobayashi M; Ohi M; Araki T; Kusunoki M
    Anticancer Res; 2017 Oct; 37(10):5797-5804. PubMed ID: 28982904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.